We are live on
!
Find out more
BOCH
Blue Owl Capital Holdings Portfolio holdings
AUM
$372M
1-Year Est. Return
78.25%
This Fund
S&P 500
This Quarter
Est. Return
+13.94%
1 Year Est. Return
+78.25%
3 Year Est. Return
+112.77%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$518M
AUM Growth
+$159M
(+44%)
Cap. Flow
+$131M
Cap. Flow
% of AUM
25.19%
Top 10 Holdings %
Top 10 Hldgs %
65.06%
Holding
140
New
98
Increased
11
Reduced
9
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nuveen Churchill Direct Lending
NCDL
|
+$70.6M |
| 2 |
ProShares UltraPro QQQ
TQQQ
|
+$22.3M |
| 3 |
Conduent
CNDT
|
+$12.3M |
| 4 |
Holley
HLLY
|
+$8.52M |
| 5 |
GAQ
Generation Asia I Acquisition Limited Class A Ordinary Shares
GAQ
|
+$5.23M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Toast
TOST
|
+$8.31M |
| 2 |
Viking Therapeutics
VKTX
|
+$5.57M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
+$5.35M |
| 4 |
TRML
Tourmaline Bio
TRML
|
+$3.09M |
| 5 |
Mineralys Therapeutics
MLYS
|
+$3.08M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 53.22% |
| 2 | Financials | 20.04% |
| 3 | Technology | 17.47% |
| 4 | Consumer Discretionary | 1.45% |
| 5 | Industrials | 1.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Nuveen Churchill Direct Lending
NCDL
$609M
| $70.4M | 13.57% |
+4,039,553
| New | +$70.6M |
|
2
Klaviyo
KVYO
$5.8B
| $42.4M | 8.18% |
1,198,270
| – | – |
|
|
TRML
3
DELISTED
Tourmaline Bio
TRML
| $39.3M | 7.59% |
1,530,401
-185,000
| -11% | -$3.09M |
|
4
Pliant Therapeutics
PLRX
$65M
| $33.7M | 6.5% |
3,004,199
| – | – |
|
5
Cullinan Oncology
CGEM
$1.06B
| $33.7M | 6.49% |
2,010,972
-38,200
| -2% | -$678K |
|
6
Blue Owl Capital
OBDC
$5.35B
| $29.8M | 5.75% |
2,045,070
| – | – |
|
7
Larimar Therapeutics
LRMR
$377M
| $27.3M | 5.26% |
4,166,829
+307,361
| +8% | +$2.47M |
|
|
8
ProShares UltraPro QQQ
TQQQ
$28.6B
| $23.6M | 4.54% |
+650,000
| New | +$22.3M |
|
9
enGene Therapeutics
ENGN
$120M
| $20.2M | 3.89% |
3,058,969
+609,142
| +25% | +$4.53M |
|
10
EverCommerce
EVCM
$2.14B
| $17M | 3.28% |
1,641,929
| – | – |
|
|
SLRN
11
DELISTED
ACELYRIN
SLRN
| $13.8M | 2.66% |
2,793,946
-132,082
| -5% | -$682K |
|
|
12
Conduent
CNDT
$253M
| $13.6M | 2.61% |
+3,363,022
| New | +$12.3M |
|
|
RPTX
13
DELISTED
Repare Therapeutics
RPTX
| $11.6M | 2.24% |
3,372,499
| – | – |
|
14
Context Therapeutics
CNTX
$56.7M
| $10.6M | 2.05% |
5,411,290
+250,000
| +5% | +$555K |
|
|
15
Ultragenyx Pharmaceutical
RARE
$2.46B
| $9.07M | 1.75% |
163,238
-105,000
| -39% | -$5.35M |
|
16
Disc Medicine
IRON
$2.81B
| $8.61M | 1.66% |
175,260
-40,000
| -19% | -$1.88M |
|
|
17
Holley
HLLY
$335M
| $7.5M | 1.45% |
+2,543,588
| New | +$8.52M |
|
|
ETWO
18
DELISTED
E2open Parent Holdings
ETWO
| $7.28M | 1.4% |
1,650,943
| – | – |
|
19
Keros Therapeutics
KROS
$197M
| $7.12M | 1.37% |
122,633
-35,000
| -22% | -$1.73M |
|
|
IMA
20
ImageneBio Inc
IMA
$63.4M
| $7.08M | 1.37% |
340,927
| – | – |
|
21
Aquestive Therapeutics
AQST
$452M
| $6.1M | 1.18% |
1,225,000
+85,000
| +7% | +$331K |
|
|
INZY
22
DELISTED
Inozyme Pharma
INZY
| $5.86M | 1.13% |
1,120,027
| – | – |
|
23
LanzaTech
LNZA
$59.9M
| $5.59M | 1.08% |
+29,265
| New | +$4.78M |
|
24
Compass Therapeutics
CMPX
$349M
| $5.3M | 1.02% |
2,879,712
+50,000
| +2% | +$62.3K |
|
|
CCC
25
CCC Intelligent Solutions
CCC
$3.55B
| $5.05M | 0.97% |
+457,104
| New | +$4.93M |
|
Similar funds
PC
GIP
DPCM
SAAM
MWM
AWA
KP
TCM
Blue Owl Capital Holdings's Q3 2024 Portfolio in Review
As of Q3 2024, Blue Owl Capital Holdings held 140 positions worth $518M, up 44% from $360M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Blue Owl Capital Holdings deployed $131M of net new capital in Q3 2024, opening 98 new positions and adding to 11 existing holdings. Its largest new stake was Nuveen Churchill Direct Lending: 4,039,553 shares worth $70.4M.
By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 72% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Ultragenyx Pharmaceutical, an estimated $5.35M trimmed.
- Blue Owl Capital Holdings's largest Q3 2024 buy was Nuveen Churchill Direct Lending: 4,039,553 shares worth $70.4M.
- Blue Owl Capital Holdings added most to enGene Therapeutics in Q3 2024, an estimated $4.53M increase.
- Blue Owl Capital Holdings's biggest Q3 2024 reduction was Ultragenyx Pharmaceutical, cutting an estimated $5.35M.
- Blue Owl Capital Holdings fully exited Toast in Q3 2024, selling an estimated $8.31M.
- Blue Owl Capital Holdings's ten largest holdings make up 65% of its $518M portfolio in Q3 2024.
- Blue Owl Capital Holdings opened 98 new positions and closed 3 in Q3 2024.
- Blue Owl Capital Holdings's portfolio value rose 44% quarter-over-quarter to $518M.
Based on Blue Owl Capital Holdings's 13F filing for Q3 2024, filed 14 Nov 2024.